Cardiovascular DiseasesAHSNCT00629954
Abuja Heart Study: Prospective Epidemiological Investigation of Cardiovascular Diseases
An observational study of Cardiovascular Diseases and High Blood Pressure, run by Healthsystem Plus at 5 sites in Nigeria.
Trial summary
This is a multi-site prospective epidemiological investigation of cardiovascular disease (CVD) among Abuja residents from the rural and metropolitan area. Read more about this study
- Who is it for?
- Ages 18 to 64 yearsHealthy volunteers can take part
- Conditions the study is for
- Cardiovascular Diseases, High Blood Pressure
- How many people
- 10,000 participants
- Where
- 5 sitesNigeria
- Study dates
- Nov 2009to Nov 2016
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 64 years
- All sexes
- Healthy volunteers accepted
- Adult
Study population: Abuja residents from the rural and metropolitan area.
Who may be able to join
- Some history of cardiovascular disease,PLWHA
- Patients have to agree to participate by signing a consent
- 18 years and older
Who cannot join
- Stroke
Trial locations and contacts
5 sites in 1 country.
Uchenna N Onyeachom contact
5 sites in 1 country
Nigeria5 sites, 5 recruiting
- Recruiting
National Hospital Abuja
Abuja, Federal Capital Territory
- Recruiting
State House Medical Center
Abuja, Federal Capital Territory
- Recruiting
Nigerian Defense Medical Center
Abuja
- Recruiting
Bwari General Hospital
Bwari, Federal Capital Territory
- Recruiting
Gwagwalada Specialist Hospital
Federal Capital Territory
About this study
Official title: Abuja Heart Study (AHS) is a Multi-site Prospective Epidemiological Investigation of Cardiovascular Disease (CVD) .
This is a multi-site prospective epidemiological investigation of cardiovascular disease (CVD) among Abuja residents from the rural and metropolitan area.
Read the detailed description
Sub-Saharan Africa continues to fight the battle of infectious diseases such as HIV/AIDS, Tuberculosis and Malaria. But given all the international efforts geared to curing and containing these diseases, and with progress made in various countries, Sub-Saharan Africa is now heading into another type of epidemic, cardiovascular disease (CVD). Predicted statistics have shown that cardiovascular diseases will become the leading cause of death in developing countries within the next 10 to 15 years, however relatively few population-based studies have examined CVD in Africa .
Although control of communicable ,childhood ,and maternal diseases has benefited from an international efforts on clinical care, policy and implementation,such large scale effort are lacking for CVD and have left both policymakers and individuals with decisions on health issues without adequate information.
Prior to the commencement of the study,series of community meetings and focus groups discussions will be held to identify ways to enhance participation. An extensive examination will include a series of questionnaires dealing with lifestyle habits, medical history, social and cultural factors, physical assessments which include height, weight,central blood pressure assessment of arterial stiffness and autonomic function and laboratory measurements for cholesterol, other lipids, glucose ,c-reactive protein among others.
- Conditions
- Cardiovascular Diseases, High Blood Pressure
- Keywords
- ABUJA HEART STUDY NIGERIA, CARDIOVASCULAR DISEASES
- Medical subject headings
- Cardiovascular Diseases, Hypertension
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| I | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
determine the roles of sociocultural factors, such as poverty,gender, literacy, stress in the development of CVD and associated risk factors
Measured: 5
Secondary outcomes (1)
familial or hereditary factors
Measured: 10
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Mar 2008 (estimated)
- Study startNov 2009
- Primary completionNov 2014 (estimated)
- Study completionNov 2016 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cardiovascular DiseasesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 10,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Healthsystem Plus
- Sponsor type
- University, hospital or other
- Collaborators
- Federal Ministry of Health, Nigeria, Akaza Research, Byrne Healthcare, Baim Institute for Clinical Research
- Responsible party
- Principal investigator, uchenna onyeachom, Healthsystem Plus
- Investigators
- Uchenna N Onyeachom, Principal investigator, Healthsystem PlusNgozi A Njepuome, Principal investigator, Abuja Heart StudyChimele Abengowe, Study chair, National Hospital, Abuja
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00629954
- Sponsor's protocol ID
- HIFA-001
- Acronym
- AHS
- Status last verified
- Aug 2012
- First submitted
- 25 Feb 2008
- Last updated
- 26 Sep 2013
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 26 Sep 2013. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Abuja Heart Study (AHS) is a Multi-site Prospective Epidemiological Investigation of Cardiovascular Disease (CVD) .
- ClinicalTrials.gov ID
- NCT00629954
- Acronym / sponsor ID
- AHS / HIFA-001
- Conditions
- Cardiovascular Diseases, High Blood Pressure
- Keywords
- ABUJA HEART STUDY NIGERIA, CARDIOVASCULAR DISEASES
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 10,000 participants (estimated)
- Lead sponsor
- Healthsystem PlusUniversity, hospital or other
- Collaborators
- Federal Ministry of Health, Nigeria, Akaza Research, Byrne Healthcare, Baim Institute for Clinical Research
- Study start
- Nov 2009
- Primary completion
- Nov 2014 (estimated)
- Study completion
- Nov 2016 (estimated)
- First posted
- 6 Mar 2008 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a multi-site prospective epidemiological investigation of cardiovascular disease (CVD) among Abuja residents from the rural and metropolitan area.
Detailed description
Sub-Saharan Africa continues to fight the battle of infectious diseases such as HIV/AIDS, Tuberculosis and Malaria. But given all the international efforts geared to curing and containing these diseases, and with progress made in various countries, Sub-Saharan Africa is now heading into another type of epidemic, cardiovascular disease (CVD). Predicted statistics have shown that cardiovascular diseases will become the leading cause of death in developing countries within the next 10 to 15 years, however relatively few population-based studies have examined CVD in Africa .
Although control of communicable ,childhood ,and maternal diseases has benefited from an international efforts on clinical care, policy and implementation,such large scale effort are lacking for CVD and have left both policymakers and individuals with decisions on health issues without adequate information.
Prior to the commencement of the study,series of community meetings and focus groups discussions will be held to identify ways to enhance participation. An extensive examination will include a series of questionnaires dealing with lifestyle habits, medical history, social and cultural factors, physical assessments which include height, weight,central blood pressure assessment of arterial stiffness and autonomic function and laboratory measurements for cholesterol, other lipids, glucose ,c-reactive protein among others.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| I | – | – |
Who may qualify
- Ages
- 18 to 64 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
- Study population
- Abuja residents from the rural and metropolitan area.
Key inclusion criteria (3 listed)
- Some history of cardiovascular disease,PLWHA
- Patients have to agree to participate by signing a consent
- 18 years and older
Key exclusion criteria (1 listed)
- Stroke
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
determine the roles of sociocultural factors, such as poverty,gender, literacy, stress in the development of CVD and associated risk factors
Time frame: 5
1 secondary outcome
familial or hereditary factors
Time frame: 10
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Sep 2013.
Related trials for Cardiovascular Diseases
Active, not recruitingPhase 3
ENDOTHELION Study Group: Effect of Bosentan in NAION Patients
Ischemic Optic Neuropathy
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Not yet recruitingPhase 2
Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma (RRMM)
RecruitingPhase 2
Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)
Multiple Myeloma
Recruiting
PAW-Hydrogel for Chronic Wound Healing
Diabetic Foot Ulcer (DFU), Pressure Ulcer (PU)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Uchenna N Onyeachom contact
Uchenna N Onyeachom principal investigator
Healthsystem Plus
Ngozi A Njepuome principal investigator
Abuja Heart Study
Chimele Abengowe study chair
National Hospital, Abuja
5 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cardiovascular Diseases and High Blood Pressure, run by Healthsystem Plus at 5 sites in Nigeria.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 26 Sep 2013. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 5 sites in Nigeria. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Uchenna N Onyeachom (uonyeachom@hvori.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
determine the roles of sociocultural factors, such as poverty,gender, literacy, stress in the development of CVD and associated risk factors (time frame: 5). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Sep 2013.